Evidence map›Paper›PMID 37626922›Full record

ArticleCells2023

The Microtubule-Targeting Agent Pretubulysin Impairs the Inflammatory Response in Endothelial Cells by a JNK-Dependent Deregulation of the Histone Acetyltransferase Brd4.

Tobias F Primke, Rebecca Ingelfinger, Mohammed A F Elewa, Igor Macinkovic, Andreas Weigert, Matthias P Fabritius, Christoph A Reichel, Angelika Ullrich, Uli Kazmaier, Luisa D Burgers and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Tobias F PrimkeInstitute of Pharmaceutical Biology, Goethe University Frankfurt, 60438 Frankfurt, Germany.
Rebecca IngelfingerInstitute of Pharmaceutical Biology, Goethe University Frankfurt, 60438 Frankfurt, Germany.
Mohammed A F ElewaInstitute of Biochemistry I, Faculty of Medicine, Goethe University Frankfurt, 60596 Frankfurt, Germany.
Igor MacinkovicInstitute of Biochemistry I, Faculty of Medicine, Goethe University Frankfurt, 60596 Frankfurt, Germany.ORCID 0000-0001-6179-560X
Andreas WeigertInstitute of Biochemistry I, Faculty of Medicine, Goethe University Frankfurt, 60596 Frankfurt, Germany.ORCID 0000-0002-7529-1952
Matthias P FabritiusDepartment of Otorhinolaryngology, Walter Brendel Centre of Experimental Medicine, University Hospital, 81377 Munich, Germany.ORCID 0000-0002-3471-4701
Christoph A ReichelDepartment of Otorhinolaryngology, Walter Brendel Centre of Experimental Medicine, University Hospital, 81377 Munich, Germany.
Angelika UllrichInstitute of Organic Chemistry, Saarland University, 66123 Saarbrücken, Germany.
Uli KazmaierInstitute of Organic Chemistry, Saarland University, 66123 Saarbrücken, Germany.ORCID 0000-0001-9756-0589
Luisa D BurgersInstitute of Pharmaceutical Biology, Goethe University Frankfurt, 60438 Frankfurt, Germany.
Robert FürstInstitute of Pharmaceutical Biology, Goethe University Frankfurt, 60438 Frankfurt, Germany.ORCID 0000-0002-9926-7578
Goethe University Frankfurt · DESaarland University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anti-inflammatory effects of depolymerizing microtubule-targeting agents on leukocytes are known for a long time, but the potential involvement of the vascular endothelium and the underlying mechanistic basis is still largely unclear. Using the recently synthesized depolymerizing microtubule-targeting agent pretubulysin, we investigated the anti-inflammatory potential of pretubulysin and other microtubule-targeting agents with respect to the TNF-induced leukocyte adhesion cascade in endothelial cells, to improve our understanding of the underlying biomolecular background. We found that treatment with pretubulysin reduces inflammation in vivo and in vitro via inhibition of the TNF-induced adhesion of leukocytes to the vascular endothelium by down-regulation of the pro-inflammatory cell adhesion molecules ICAM-1 and VCAM-1 in a JNK-dependent manner. The underlying mechanism includes JNK-induced deregulation and degradation of the histone acetyltransferase Bromodomain-containing protein 4. This study shows that depolymerizing microtubule-targeting agents, in addition to their established effects on leukocytes, also significantly decrease the inflammatory activation of vascular endothelial cells. These effects are not based on altered pro-inflammatory signaling cascades, but require deregulation of the capability of cells to enter constructive transcription for some genes, setting a baseline for further research on the prominent anti-inflammatory effects of depolymerizing microtubule-targeting agents.

Indexed as

Endothelial CellsNuclear ProteinsHistone AcetyltransferasesMicrotubulesOligopeptidesTranscription FactorsHistone AcetyltransferasesNuclear ProteinsOligopeptidespretubulysinTranscription Factorsbromodomain-containing protein 4cell adhesion moleculesc-jun-N-terminal kinaseendotheliuminflammationleukocyte adhesion cascademicrotubule-targeting agentsNFκB

Identifiers

PMID37626922
PMCPMC10453553
OpenAlexW4386031922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.